Browse KITLG

Summary
SymbolKITLG
NameKIT ligand
Aliases SCF; Kitl; KL-1; FPH2; stem cell factor; steel factor; familial progressive hyperpigmentation 2; FPHH; SHEP7 ......
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Cell membrane; Single-pass type I membrane protein.; SUBCELLULAR LOCATION: Isoform 2: Cytoplasm Cytoplasm, cytoskeleton Cell membrane Single-pass type I membrane protein Cell projection, lamellipodium Cell projection, filopodium ; SUBCELLULAR LOCATION: Soluble KIT ligand: Secreted.
Domain PF02404 Stem cell factor
Function

Ligand for the receptor-type protein-tyrosine kinase KIT. Plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. KITLG/SCF binding can activate several signaling pathways. Promotes phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and subsequent activation of the kinase AKT1. KITLG/SCF and KIT also transmit signals via GRB2 and activation of RAS, RAF1 and the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. KITLG/SCF and KIT promote activation of STAT family members STAT1, STAT3 and STAT5. KITLG/SCF and KIT promote activation of PLCG1, leading to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. KITLG/SCF acts synergistically with other cytokines, probably interleukins.

> Gene Ontology
 
Biological Process GO:0001541 ovarian follicle development
GO:0001667 ameboidal-type cell migration
GO:0001755 neural crest cell migration
GO:0001776 leukocyte homeostasis
GO:0002262 myeloid cell homeostasis
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0002683 negative regulation of immune system process
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002761 regulation of myeloid leukocyte differentiation
GO:0002763 positive regulation of myeloid leukocyte differentiation
GO:0006260 DNA replication
GO:0006275 regulation of DNA replication
GO:0006644 phospholipid metabolic process
GO:0006650 glycerophospholipid metabolic process
GO:0007265 Ras protein signal transduction
GO:0007548 sex differentiation
GO:0008406 gonad development
GO:0008584 male gonad development
GO:0008585 female gonad development
GO:0010623 programmed cell death involved in cell development
GO:0014031 mesenchymal cell development
GO:0014032 neural crest cell development
GO:0014033 neural crest cell differentiation
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0022602 ovulation cycle process
GO:0030099 myeloid cell differentiation
GO:0030258 lipid modification
GO:0030318 melanocyte differentiation
GO:0030335 positive regulation of cell migration
GO:0032844 regulation of homeostatic process
GO:0032845 negative regulation of homeostatic process
GO:0033023 mast cell homeostasis
GO:0033024 mast cell apoptotic process
GO:0033025 regulation of mast cell apoptotic process
GO:0033026 negative regulation of mast cell apoptotic process
GO:0033028 myeloid cell apoptotic process
GO:0033032 regulation of myeloid cell apoptotic process
GO:0033033 negative regulation of myeloid cell apoptotic process
GO:0033674 positive regulation of kinase activity
GO:0035162 embryonic hemopoiesis
GO:0035234 ectopic germ cell programmed cell death
GO:0038034 signal transduction in absence of ligand
GO:0040017 positive regulation of locomotion
GO:0042698 ovulation cycle
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0043473 pigmentation
GO:0045137 development of primary sexual characteristics
GO:0045634 regulation of melanocyte differentiation
GO:0045636 positive regulation of melanocyte differentiation
GO:0045637 regulation of myeloid cell differentiation
GO:0045639 positive regulation of myeloid cell differentiation
GO:0045740 positive regulation of DNA replication
GO:0045860 positive regulation of protein kinase activity
GO:0046486 glycerolipid metabolic process
GO:0046488 phosphatidylinositol metabolic process
GO:0046545 development of primary female sexual characteristics
GO:0046546 development of primary male sexual characteristics
GO:0046578 regulation of Ras protein signal transduction
GO:0046579 positive regulation of Ras protein signal transduction
GO:0046660 female sex differentiation
GO:0046661 male sex differentiation
GO:0046834 lipid phosphorylation
GO:0046854 phosphatidylinositol phosphorylation
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0048066 developmental pigmentation
GO:0048070 regulation of developmental pigmentation
GO:0048087 positive regulation of developmental pigmentation
GO:0048511 rhythmic process
GO:0048568 embryonic organ development
GO:0048608 reproductive structure development
GO:0048762 mesenchymal cell differentiation
GO:0048863 stem cell differentiation
GO:0048864 stem cell development
GO:0048872 homeostasis of number of cells
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0050900 leukocyte migration
GO:0050931 pigment cell differentiation
GO:0050932 regulation of pigment cell differentiation
GO:0050942 positive regulation of pigment cell differentiation
GO:0051052 regulation of DNA metabolic process
GO:0051054 positive regulation of DNA metabolic process
GO:0051056 regulation of small GTPase mediated signal transduction
GO:0051057 positive regulation of small GTPase mediated signal transduction
GO:0051272 positive regulation of cellular component movement
GO:0060485 mesenchyme development
GO:0061458 reproductive system development
GO:0070661 leukocyte proliferation
GO:0070662 mast cell proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0070666 regulation of mast cell proliferation
GO:0070668 positive regulation of mast cell proliferation
GO:0071425 hematopoietic stem cell proliferation
GO:0071887 leukocyte apoptotic process
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0072089 stem cell proliferation
GO:0072091 regulation of stem cell proliferation
GO:0097191 extrinsic apoptotic signaling pathway
GO:0097192 extrinsic apoptotic signaling pathway in absence of ligand
GO:1902033 regulation of hematopoietic stem cell proliferation
GO:1902035 positive regulation of hematopoietic stem cell proliferation
GO:1902105 regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1903706 regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
GO:2000106 regulation of leukocyte apoptotic process
GO:2000107 negative regulation of leukocyte apoptotic process
GO:2000147 positive regulation of cell motility
GO:2000648 positive regulation of stem cell proliferation
Molecular Function GO:0005085 guanyl-nucleotide exchange factor activity
GO:0005088 Ras guanyl-nucleotide exchange factor activity
GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0005173 stem cell factor receptor binding
GO:0008083 growth factor activity
GO:0035004 phosphatidylinositol 3-kinase activity
GO:0046934 phosphatidylinositol-4,5-bisphosphate 3-kinase activity
GO:0052813 phosphatidylinositol bisphosphate kinase activity
Cellular Component GO:0030027 lamellipodium
GO:0030175 filopodium
GO:0031252 cell leading edge
GO:0098858 actin-based cell projection
> KEGG and Reactome Pathway
 
KEGG hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
hsa04060 Cytokine-cytokine receptor interaction
hsa04151 PI3K-Akt signaling pathway
hsa04640 Hematopoietic cell lineage
hsa04916 Melanogenesis
Reactome R-HSA-170984: ARMS-mediated activation
R-HSA-1280218: Adaptive Immune System
R-HSA-422475: Axon guidance
R-HSA-2219530: Constitutive Signaling by Aberrant PI3K in Cancer
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-180292: GAB1 signalosome
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-199418: Negative regulation of the PI3K/AKT network
R-HSA-2219528: PI3K/AKT Signaling in Cancer
R-HSA-198203: PI3K/AKT activation
R-HSA-6811558: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-1257604: PIP3 activates AKT signaling
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-1433559: Regulation of KIT signaling
R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
Summary
SymbolKITLG
NameKIT ligand
Aliases SCF; Kitl; KL-1; FPH2; stem cell factor; steel factor; familial progressive hyperpigmentation 2; FPHH; SHEP7 ......
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between KITLG and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between KITLG and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
17885078Colon CarcinomaInhibit immunity (T cell function)Mice bearing tumor cells with SCF siRNA knockdown exhibited significantly reduced MDSC expansion and restored proliferative responses of tumor-infiltrating T cells. Furthermore, the prevention of MDSC accumulation in conjunction with immune activation therapy showed synergistic therapeutic effect when treating mice bearing large tumors.
24144734Breast CarcinomaInhibit immunityA functional c-Kit/Kit ligand (KitL) signalling network is required for tumour angiogenesis and growth, and therefore the c-Kit/KitL system might well be a suitable target for the cancer immunotherapy approach. DNA vaccination, interferes with tumour vessel formation and transplanted tumour growth in vivo. Histological analysis demonstrates that, while tumour cell proliferation and vessel stabilisation are impaired, vessel permeability is increased in mice that produce mbKitL-targeting antibodies.
Summary
SymbolKITLG
NameKIT ligand
Aliases SCF; Kitl; KL-1; FPH2; stem cell factor; steel factor; familial progressive hyperpigmentation 2; FPHH; SHEP7 ......
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of KITLG in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolKITLG
NameKIT ligand
Aliases SCF; Kitl; KL-1; FPH2; stem cell factor; steel factor; familial progressive hyperpigmentation 2; FPHH; SHEP7 ......
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of KITLG in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6750.154
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.8130.422
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5710.463
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3150.504
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6490.623
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1110.942
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1690.68
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0390.975
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2860.839
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5570.61
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.0180.14
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2280.117
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of KITLG in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382707.4-7.40.169
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolKITLG
NameKIT ligand
Aliases SCF; Kitl; KL-1; FPH2; stem cell factor; steel factor; familial progressive hyperpigmentation 2; FPHH; SHEP7 ......
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KITLG. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolKITLG
NameKIT ligand
Aliases SCF; Kitl; KL-1; FPH2; stem cell factor; steel factor; familial progressive hyperpigmentation 2; FPHH; SHEP7 ......
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KITLG. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KITLG.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolKITLG
NameKIT ligand
Aliases SCF; Kitl; KL-1; FPH2; stem cell factor; steel factor; familial progressive hyperpigmentation 2; FPHH; SHEP7 ......
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KITLG. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolKITLG
NameKIT ligand
Aliases SCF; Kitl; KL-1; FPH2; stem cell factor; steel factor; familial progressive hyperpigmentation 2; FPHH; SHEP7 ......
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of KITLG expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolKITLG
NameKIT ligand
Aliases SCF; Kitl; KL-1; FPH2; stem cell factor; steel factor; familial progressive hyperpigmentation 2; FPHH; SHEP7 ......
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between KITLG and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolKITLG
NameKIT ligand
Aliases SCF; Kitl; KL-1; FPH2; stem cell factor; steel factor; familial progressive hyperpigmentation 2; FPHH; SHEP7 ......
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting KITLG collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.